Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on July 27, 2023, covering events occurring on July 26, 2023. The company is an emerging growth company incorporated in Nevada with its principal executive offices in Boca Raton, Florida.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event regarding a trading plan and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the termination of a Rule 10b5-1 trading plan established by CTI Holdings, Inc. ("CTI"). CTI, whose majority shareholder is Timothy J. Schroeder (a member of the Company's board of directors), had previously established a plan on November 16, 2022, to trade 60,000 shares of the Company's common stock. This plan was terminated on July 26, 2023.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific event of the trading plan termination.
Investor Verification Checklist
- Verify the termination date of the CTI Holdings, Inc. trading plan (July 26, 2023).
- Confirm the number of shares originally covered by the terminated plan (60,000 shares).
- Review the relationship between CTI Holdings, Inc. and Timothy J. Schroeder, a board member.
- Check prior filings (specifically the November 21, 2022 Form 8-K) for the original terms of the trading plan.